A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death. Mannion et al.

Original data from the images and western blots from the paper: A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death.

本数据集来源于论文《靶向RIPK1（Receptor Interacting Serine/Threonine Kinase 1）的PROTAC（Proteolysis Targeting Chimeras）降解剂通过增强免疫原性细胞死亡实现强效抗肿瘤活性》中的图像与免疫印迹（Western Blot）原始实验数据。